SCHEMBL3389079

SCHEMBL3389079

Cc1[nH]c2ccc(OCc3ccccc3)cc2c1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.61
GABRA1 P14867 3/20 0.56
GABRG2 P18507 3/20 0.56
GABRB3 P28472 3/20 0.56
GABRA5 P31644 3/20 0.56
GABRA3 P34903 3/20 0.56
GABRA2 P47869 3/20 0.56
KDM4E B2RXH2 3/20 0.56
HPGD P15428 3/20 0.56
ALDH1A1 P00352 3/20 0.56
HSD17B10 Q99714 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
SRD5A2 P31213 1/20 0.56
MAPT P10636 4/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.56
MAOA P21397 1/20 0.55
MAOB P27338 1/20 0.55
GAA P10253 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13309192 0.88 GABRA1 (0.67) TRPM8GABRA1GABRG2GABRB3GABRA5
SCHEMBL8637415 0.84 KDM4E (0.55) TRPM8GABRA1GABRG2GABRB3GABRA5
SCHEMBL5504619 0.83 KDM4E (0.69) TRPM8GABRA1GABRG2GABRB3GABRA5
SCHEMBL13802390 0.82 AKR1C2 (0.69) TRPM8GABRA1GABRG2GABRB3GABRA5
SCHEMBL7848053 0.82 TRPM8 (0.61) TRPM8GABRA1GABRG2GABRB3GABRA5
SCHEMBL28491260 0.81 TRPM8 (0.69) TRPM8GABRA1GABRG2GABRB3GABRA5
SCHEMBL29751790 0.81 TRPM8 (0.69) TRPM8GABRA1GABRG2GABRB3GABRA5
SCHEMBL6316345 0.79 GAA (0.50) TRPM8GABRA1GABRG2GABRB3GABRA5
SCHEMBL6314661 0.79 GAA (0.50) TRPM8GABRA1GABRG2GABRB3GABRA5
SCHEMBL1434196 0.79 ALDH1A1 (0.67) KDM4EHPGDALDH1A1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737173-B2 Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity ALLERGAN, INC. (US) 2010-06-15 US disclosed
CN-101460458-A Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity ALLERGAN INC (US) 2009-06-17 CN disclosed
EP-1984334-A2 INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY Allergan, Inc. (US) 2008-10-29 EP disclosed
WO-2007095561-A2 INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2007-08-23 WO disclosed
US-20070191313-A1 INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191313-A1 INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY S1PR3, S1PR1, S1PR2 TRPM8 726/4885GABRA1 1920/4885GABRG2 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.